The trials
Cingi et al. (2008) — the best-known study
Mete Cingi and colleagues at Eskişehir Osmangazi University published what is still the most rigorous study on spirulina for allergic rhinitis in 2008. The trial enrolled 150 patients with confirmed allergic rhinitis and randomised them to 2 g/day of spirulina or placebo for 12 weeks. It was double-blinded.
Results:
- Spirulina significantly reduced all measured symptom scores — nasal discharge, sneezing, nasal congestion, and itching — compared to placebo.
- The improvement in nasal discharge and sneezing was particularly pronounced. Congestion showed a smaller effect.
- Patients reported meaningfully better quality of life in the spirulina arm than in the placebo arm.
- The effect was detectable by week 6 and continued through the end of the trial.
This is a 150-person double-blinded RCT — a genuinely solid study design. It is not perfect (single site, 12 weeks, no long-term follow-up), but it’s substantially better than most evidence behind commonly used hay fever supplements.
Mao et al. (2005) — the UC Davis study
An earlier, smaller study by Trent Mao and colleagues at UC Davis randomised 36 patients with perennial allergic rhinitis to spirulina or placebo for 12 weeks. The spirulina group showed significantly higher levels of IL-4 inhibition — a cytokine central to the Th2 immune response that drives allergic inflammation.
Where Cingi measured symptoms directly, Mao measured immune markers — finding that spirulina appeared to shift immune function away from the Th2 dominance characteristic of allergic disease. The two studies complement each other: mechanism (Mao) and clinical outcome (Cingi) both pointing the same way.
Why phycocyanin is the likely mechanism
Allergic rhinitis is primarily a Th2-mediated inflammatory response: IgE antibodies, mast cell activation, histamine release, and a cascade of pro-inflammatory cytokines. Phycocyanin — spirulina’s blue pigment — inhibits several points in this cascade:
- Inhibits COX-2, reducing prostaglandin production (the pathway some antihistamines and NSAIDs target by other routes).
- Reduces reactive oxygen species, which amplify mast cell degranulation.
- The IL-4 suppression found in the Mao study is consistent with a Th2-modulating effect.
This is the “plausible mechanism” requirement that elevates spirulina for rhinitis above the evidence standard for most supplement claims. The mechanism is real, the clinical signal is real, and they are consistent with each other.
What the community says
In the Facebook community (14,000+ members, 19 years of discussion), seasonal allergy is one of the most frequently reported spirulina benefits — anecdotally, the most consistently reported. Many members with mild-to-moderate hay fever report that consistent daily spirulina use reduces their need for antihistamines during the pollen season.
This is anecdote, not evidence. But the anecdote is consistent with the clinical data in a way that should not be dismissed.
Dose and timing
Both trials used 2 g/day for 12 weeks. The effect in the Cingi trial was detectable at 6 weeks. For seasonal hay fever, starting spirulina 4–6 weeks before your typical pollen season gives it time to reach the point where most of the benefit was observed in the trials.
Taking it year-round is likely fine and may mean you carry some baseline anti-inflammatory benefit into the high-pollen months without needing to think about timing. Either approach appears to work, based on the available evidence.
Realistic expectations
Spirulina at 2 g/day is not a replacement for prescription antihistamines in people with severe seasonal allergic rhinitis — the effect sizes in the trials are real but modest. What it appears to do is reduce the overall symptom burden meaningfully, in a way that may reduce medication dependence for people with mild-to-moderate symptoms.
For context: the improvement in the Cingi trial was clinically meaningful — patients reported better quality of life, and symptom scores dropped significantly — but it did not produce complete relief.
The benefit is likely to be most noticeable in people with mild-to-moderate hay fever who are looking to reduce medication or want a non-pharmaceutical tool alongside standard management.
Quality note
If you’re using spirulina specifically for its phycocyanin-related effects on allergic rhinitis, phycocyanin content matters more than usual. Phycocyanin is the likely active compound; a spirulina with a published phycocyanin percentage above 14% will deliver more of it per gram than a commodity product with 8–10%. See our quality guide for how to find this figure on a Certificate of Analysis.